论文部分内容阅读
目的:对食管癌放疗后复发患者行再程放疗的临床效果进行探讨,观察其临床价值。方法:选取我院2011年10月-2013年10月期间经放疗后再复发的食管癌患者86例,随机分成对照组与治疗组,对照组给予单纯三维适形放疗的方式,治疗组给予三维适形放-化疗联合的方式,比较两组患者在近期临床缓解率,不良反应的发生率及前3年的生存率之间的差别。结果:在治疗结束后,对照组与治疗组患者近期临床缓解率分别为74.4%、90.7%,差异具有统计学意义P<0.05;治疗组与对照组比较,第1、2、3年的生存率更高一点,但统计学差异不明显(P>0.05);治疗组的不良反应发生率明显高于对照组,差异具有统计学意义(P<0.05)。结论:食管癌放疗后复发患者行再程放疗的临床效果显著,是一种有效的治疗手段,但不良反应发生率较高,因此在临床上应慎重应用。
Objective: To investigate the clinical effect of reradiation after esophageal cancer recurrence after radiotherapy and observe its clinical value. Methods: Eighty-six patients with esophageal cancer who relapsed after radiotherapy from October 2011 to October 2013 in our hospital were randomly divided into control group and treatment group. The control group was treated with simple three-dimensional conformal radiotherapy. The treatment group received three-dimensional Conformal radiotherapy - chemotherapy combined approach to compare the two groups of patients in the near future the clinical remission rate, the incidence of adverse reactions and the difference between the first 3 years of survival. Results: At the end of treatment, the recent clinical remission rates of the control group and the treatment group were 74.4% and 90.7% respectively, the difference was statistically significant (P <0.05); the survival rate of the first, second and third years in the treatment group and the control group The rate of adverse reaction in the treatment group was significantly higher than that in the control group, the difference was statistically significant (P <0.05). Conclusion: The clinical effect of reradiation after esophageal cancer recurrence after radiotherapy is significant. It is an effective treatment, but the incidence of adverse reactions is high, so it should be used cautiously clinically.